New drug litfulo monitored in 3,000 patients for hair loss control
NCT ID NCT07152119
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This study follows 3,000 people in Korea with severe alopecia areata who are starting Litfulo. Researchers will track side effects and how well the drug regrows hair over 48 weeks. The goal is to confirm safety and effectiveness in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer, Inc
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.